Investors & Media

Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.

Latest News

Medigene expands patent protection of its technologies in key markets, the USA and Europe


Participation at upcoming virtual conferences


Dr. Anthony Man appointed to Supervisory Board


The Medigene Share

The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000. 

show medigene share


20 - 21 Jan 2021

5th Annual Onco Cell Therapy Summit

08 - 12 Feb 2021

TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

16 - 18 Feb 2021

CAR-TCR Europe

23 - 25 Feb 2021

Immuno-Oncology 360°

25 Mar 2021

Annual Report 2020

11 May 2021

Quarterly Statement Q1 2021

08 - 10 Jun 2021

TCR-Based Therapies Summit

24 Jun 2021

Annual General Meeting 2021

12 Aug 2021

6-Month Report 2021

Corporate Governance

Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.

read more

press photos

Laboratory work

DownLoad (9 MB)

Laboratory work (6)

Cell culture work

DownLoad (4 MB)

Laboratory work (7)

Cell sorting

DownLoad (353 KB)

Contact person

Dr Gary Waanders
Vice President Investor Relations
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20

Dr. Anna Niedl
Director Investor Relations
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20